Medicine recalls
|
| |
| Canada: Apo-Fluoxetine: The impurities are out of specification and out of trend |
| |
Health Canada announces that Apotex Inc. is recalling two lots of Apo-Fluoxetine 20mg capsule (lot number: VM4608, VM4612) and one lot of Apo-Fluoxetine 10mg capsule (lot number: VM4598) from retailers because the impurities are out of specification and out of trend in the affected lot.
The product is indicated for depression, bulimia nervosa and obsessive-compulsive disorder.
Please refer to the following website in Health Canada for details:
http://recalls-rappels.canada.ca/en/alert-recall/apo-fluoxetine-impurities-are-out-specification-and-out-trend
In Hong Kong, Apo-Fluoxetine Cap 20mg (HK-41383), Apo-Fluoxetine Capsules 20mg (HK-68820), Apo-Fluoxetine Cap 10mg (HK-41382) and Apo-Fluoxetine Capsules 10mg (HK-68819) are pharmaceutical products registered by Hind Wing Co Ltd (Hind Wing). All products are prescription-only medicines. Hind Wing has been contacted regarding the above issue and their reply is pending.
On 10 Apr 2026, the Department of Health (DH) endorsed Hind Wing to recall one batch of Apo-Fluoxetine Capsules 20mg (HK-68820) (batch number: VM4608) from the market as a precautionary measure due to a potential quality issue. A recall statement was posted on the Drug Office website on the same date.
Ends/ Saturday, Apr 11, 2026
Issued at HKT 12:00
As confirmed with Hind Wing, only one batch of Apo-Fluoxetine Capsules 20mg (HK-68820) (batch number: VM4608) has been imported into Hong Kong. The rest of the affected batches have not been imported into Hong Kong.
Content last updated: Monday, Apr 13, 2026
|
| |
|
